Advertisement

Journal of Pharmacokinetics and Pharmacodynamics

, Volume 46, Issue 1, pp 89–101 | Cite as

Indirect pharmacodynamic models for responses with circadian removal

  • Vivaswath S. Ayyar
  • Wojciech Krzyzanski
  • William J. JuskoEmail author
Original Paper
  • 52 Downloads

Abstract

Rhythmicity in baseline responses over a 24-h period for an indirect pharmacological effect R(t) can arise from either a periodic time-dependent input rate \( k_{in} \left( t \right) \) or a periodic time-dependent loss constant \( k_{out} \left( t \right) \). If either \( k_{in} \left( t \right) \) or \( k_{out} \left( t \right) \) follows some nonstationary biological rhythm (e.g., circadian), then the response R(t) also displays a periodic behavior. Indirect response models assuming time-dependent input rates \( \left[ {k_{in} \left( t \right)} \right] \) have been utilized to capture drug effects on various physiological responses such as hormone suppression, immune cell trafficking, and gene expression in tissues. This paradigm was extended to consider responses with circadian-controlled loss \( \left[ {k_{out} \left( t \right)} \right] \) mechanisms. Theoretical equations describing this model are presented and simulations were performed to examine expected response behaviors. The model was able to capture the chronobiology and pharmacodynamics of applicable drug responses, including the uricosuric effects of lesinurad in humans, suppression of the beta amyloid (Aβ) peptide by a gamma-secretase inhibitor in mouse brain, and the modulation of extracellular dopamine by a dopamine transporter inhibitor in rat brain. This type of model has a mechanistic basis and shows utility for capturing drug responses displaying nonstationary baselines controlled by removal mechanism(s).

Keywords

Circadian rhythm Nonstationary baseline Pharmacodynamics Indirect response model Periodic removal Mathematical modeling 

Notes

Acknowledgements

This work was supported by the National Institutes of Health - National Institute of General Medical Sciences [Grant GM24211].

Supplementary material

10928_2019_9620_MOESM1_ESM.xlsx (702 kb)
Supplementary material 1 (XLSX 702 kb)
10928_2019_9620_MOESM2_ESM.docx (829 kb)
Supplementary material 2 (DOCX 829 kb)
10928_2019_9620_MOESM3_ESM.docx (33 kb)
Supplementary material 3 (DOCX 32 kb)

References

  1. 1.
    Sukumaran S, Almon RR, DuBois DC, Jusko WJ (2010) Circadian rhythms in gene expression: relationship to physiology, disease, drug disposition and drug action. Adv Drug Deliv Rev 62:904–917CrossRefGoogle Scholar
  2. 2.
    Dayneka NL, Garg V, Jusko WJ (1993) Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm 21:457–478CrossRefGoogle Scholar
  3. 3.
    Jusko WJ, Ko HC (1994) Physiologic indirect response models characterize diverse types of pharmacodynamic effects. Clin Pharmacol Ther 56:406–419CrossRefGoogle Scholar
  4. 4.
    Sharma A, Jusko WJ (1998) Characteristics of indirect pharmacodynamic models and applications to clinical drug responses. Br J Clin Pharmacol 45:229–239CrossRefGoogle Scholar
  5. 5.
    Chakraborty A, Krzyzanski W, Jusko WJ (1999) Mathematical modeling of circadian cortisol concentrations using indirect response models: comparison of several methods. J Pharmacokinet Biopharm 27:23–43CrossRefGoogle Scholar
  6. 6.
    Bruguerolle B (1998) Chronopharmacokinetics. Current status. Clin Pharmacokinet 35:83–94CrossRefGoogle Scholar
  7. 7.
    Harris BE, Song R, Soong SJ, Diasio RB (1990) Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 50:197–201Google Scholar
  8. 8.
    Harris BE, Song RL, Soong SJ, Diasio RB (1989) Circadian variation of 5-fluorouracil catabolism in isolated perfused rat liver. Cancer Res 49:6610–6614Google Scholar
  9. 9.
    Roh JH, Huang Y, Bero AW, Kasten T, Stewart FR, Bateman RJ, Holtzman DM (2012) Disruption of the sleep-wake cycle and diurnal fluctuation of beta-amyloid in mice with Alzheimer’s disease pathology. Sci Transl Med 4:150ra122CrossRefGoogle Scholar
  10. 10.
    Wang Q, Yu X, Li L, Zheng J (2014) Inhibition of amyloid-beta aggregation in Alzheimer’s disease. Curr Pharm Des 20:1223–1243CrossRefGoogle Scholar
  11. 11.
    Moussa CE (2017) Beta-secretase inhibitors in phase I and phase II clinical trials for Alzheimer’s disease. Expert Opin Investig Drugs 26:1131–1136CrossRefGoogle Scholar
  12. 12.
    Iliff JJ, Wang M, Liao Y, Plogg BA, Peng W, Gundersen GA, Benveniste H, Vates GE, Deane R, Goldman SA, Nagelhus EA, Nedergaard M (2012) A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid beta. Sci Transl Med 4:147ra111CrossRefGoogle Scholar
  13. 13.
    Xie L, Kang H, Xu Q, Chen MJ, Liao Y, Thiyagarajan M, O’Donnell J, Christensen DJ, Nicholson C, Iliff JJ, Takano T, Deane R, Nedergaard M (2013) Sleep drives metabolite clearance from the adult brain. Science 342:373–377CrossRefGoogle Scholar
  14. 14.
    Boespflug EL, Iliff JJ (2018) The emerging relationship between interstitial fluid-cerebrospinal fluid exchange, amyloid-beta, and sleep. Biol Psychiatry 83:328–336CrossRefGoogle Scholar
  15. 15.
    Tarasoff-Conway JM, Carare RO, Osorio RS, Glodzik L, Butler T, Fieremans E, Axel L, Rusinek H, Nicholson C, Zlokovic BV, Frangione B, Blennow K, Menard J, Zetterberg H, Wisniewski T, de Leon MJ (2016) Clearance systems in the brain—implications for Alzheimer disease. Nat Rev Neurol 12:248CrossRefGoogle Scholar
  16. 16.
    Castaneda TR, de Prado BM, Prieto D, Mora F (2004) Circadian rhythms of dopamine, glutamate and GABA in the striatum and nucleus accumbens of the awake rat: modulation by light. J Pineal Res 36:177–185CrossRefGoogle Scholar
  17. 17.
    Ferris MJ, España RA, Locke JL, Konstantopoulos JK, Rose JH, Chen R, Jones SR (2014) Dopamine transporters govern diurnal variation in extracellular dopamine tone. Proc Natl Acad Sci USA 111:E2751–E2759CrossRefGoogle Scholar
  18. 18.
    Sleipness EP, Sorg BA, Jansen HT (2007) Diurnal differences in dopamine transporter and tyrosine hydroxylase levels in rat brain: dependence on the suprachiasmatic nucleus. Brain Res 1129:34–42CrossRefGoogle Scholar
  19. 19.
    Maiuolo J, Oppedisano F, Gratteri S, Muscoli C, Mollace V (2016) Regulation of uric acid metabolism and excretion. Int J Cardiol 213:8–14CrossRefGoogle Scholar
  20. 20.
    So A, Thorens B (2010) Uric acid transport and disease. J Clin Invest 120:1791–1799CrossRefGoogle Scholar
  21. 21.
    Sennels HP, Jorgensen HL, Goetze JP, Fahrenkrug J (2012) Rhythmic 24-h variations of frequently used clinical biochemical parameters in healthy young males—the Bispebjerg study of diurnal variations. Scand J Clin Lab Invest 72:287–295CrossRefGoogle Scholar
  22. 22.
    Yu KH, Luo SF, Tsai WP, Huang YY (2004) Intermittent elevation of serum urate and 24-h urinary uric acid excretion. Rheumatology 43:1541–1545CrossRefGoogle Scholar
  23. 23.
    Koopman MG, Koomen GC, Krediet RT, de Moor EA, Hoek FJ, Arisz L (1989) Circadian rhythm of glomerular filtration rate in normal individuals. Clin Sci (Lond) 77:105–111CrossRefGoogle Scholar
  24. 24.
    Diaz-Torne C, Perez-Herrero N, Perez-Ruiz F (2015) New medications in development for the treatment of hyperuricemia of gout. Curr Opin Rheumatol 27:164–169CrossRefGoogle Scholar
  25. 25.
    D’Argenio D, Schumitzky A, Wang X (2009) ADAPT 5 User’s Guide: Pharmacokinetic/pharmacodynamic Systems Analysis Software. BioMedical Simulations Resource, Los AngelesGoogle Scholar
  26. 26.
    Sun YN, Jusko WJ (1999) Role of baseline parameters in determining indirect pharmacodynamic responses. J Pharm Sci 88:987–990CrossRefGoogle Scholar
  27. 27.
    Toyn JH, Thompson LA, Lentz KA, Meredith JE Jr, Burton CR, Sankaranararyanan S, Guss V, Hall T, Iben LG, Krause CM, Krause R, Lin XA, Pierdomenico M, Polson C, Robertson AS, Denton RR, Grace JE, Morrison J, Raybon J, Zhuo X, Snow K, Padmanabha R, Agler M, Esposito K, Harden D, Prack M, Varma S, Wong V, Zhu Y, Zvyaga T, Gerritz S, Marcin LR, Higgins MA, Shi J, Wei C, Cantone JL, Drexler DM, Macor JE, Olson RE, Ahlijanian MK, Albright CF (2014) Identification and preclinical pharmacology of the gamma-secretase modulator BMS-869780. Int J Alzheimers Dis 2014:431858Google Scholar
  28. 28.
    Lu Y, Barton HA, Leung L, Zhang L, Hajos-Korcsok E, Nolan CE, Liu J, Becker SL, Wood KM, Robshaw AE, Taylor CK, O’Neill BT, Brodney MA, Riddell D (2013) Cerebrospinal fluid beta-amyloid turnover in the mouse, dog, monkey and human evaluated by systematic quantitative analyses. Neurodegener Dis 12:36–50CrossRefGoogle Scholar
  29. 29.
    Shen Z, Rowlings C, Kerr B, Hingorani V, Manhard K, Quart B, Yeh LT, Storgard C (2015) Pharmacokinetics, pharmacodynamics, and safety of lesinurad, a selective uric acid reabsorption inhibitor, in healthy adult males. Drug Des Devel Ther 9:3423–3434CrossRefGoogle Scholar
  30. 30.
    Campion DS, Bluestone R, Klinenberg JR (1973) Uric acid: characterization of its interaction with human serum albumin. J Clin Invest 52:2383–2386CrossRefGoogle Scholar
  31. 31.
    Raje S, Cao J, Newman AH, Gao H, Eddington ND (2003) Evaluation of the blood-brain barrier transport, population pharmacokinetics, and brain distribution of benztropine analogs and cocaine using in vitro and in vivo techniques. J Pharmacol Exp Ther 307:801–808CrossRefGoogle Scholar
  32. 32.
    Raje S, Cornish J, Newman AH, Cao J, Katz JL, Eddington ND (2005) Pharmacodynamic assessment of the benztropine analogues AHN-1055 and AHN-2005 using intracerebral microdialysis to evaluate brain dopamine levels and pharmacokinetic/pharmacodynamic modeling. Pharm Res 22:603–612CrossRefGoogle Scholar
  33. 33.
    Yavich L, Forsberg MM, Karayiorgou M, Gogos JA, Mannisto PT (2007) Site-specific role of catechol-O-methyltransferase in dopamine overflow within prefrontal cortex and dorsal striatum. J Neurosci 27:10196–10209CrossRefGoogle Scholar
  34. 34.
    Gries JM, Benowitz N, Verotta D (1996) Chronopharmacokinetics of nicotine. Clin Pharmacol Ther 60:385–395CrossRefGoogle Scholar
  35. 35.
    Lemmer B, Nold G (1991) Circadian changes in estimated hepatic blood flow in healthy subjects. Br J Clin Pharmacol 32:627–629CrossRefGoogle Scholar
  36. 36.
    Levi F, Schibler U (2007) Circadian rhythms: mechanisms and therapeutic implications. Annu Rev Pharmacol Toxicol 47:593–628CrossRefGoogle Scholar
  37. 37.
    Sukumaran S, Xue B, Jusko WJ, DuBois DC, Almon RR (2010) Circadian variations in gene expression in rat abdominal adipose tissue and relationship to physiology. Physiol Genomics 42A:141–152CrossRefGoogle Scholar
  38. 38.
    Heegaard NHH, Carlsen AL, Lilje B, Ng KL, Rønne ME, Jørgensen HL, Sennels H, Fahrenkrug J (2016) Diurnal variations of human circulating cell-free micro-RNA. PLoS One 11:e0160577–e0160577CrossRefGoogle Scholar
  39. 39.
    Koch G, Schropp J (2018) Delayed logistic indirect response models: realization of oscillating behavior. J Pharmacokinet Pharmacodyn 45:49–58CrossRefGoogle Scholar
  40. 40.
    Sukumaran S, Jusko WJ, DuBois DC, Almon RR (2011) Mechanistic modeling of the effects of glucocorticoids and circadian rhythms on adipokine expression. J Pharmacol Exp Ther 337:734–746CrossRefGoogle Scholar
  41. 41.
    Boden G, Ruiz J, Urbain JL, Chen X (1996) Evidence for a circadian rhythm of insulin secretion. Am J Physiol 271:E246–252Google Scholar
  42. 42.
    Krzyzanski W, Chakraborty A, Jusko WJ (2000) Algorithm for application of Fourier analysis for biorhythmic baselines of pharmacodynamic indirect response models. Chronobiol Int 17:77–93CrossRefGoogle Scholar
  43. 43.
    Krzyzanski W, Jusko WJ (2001) Indirect pharmacodynamic models for responses with multicompartmental distribution or polyexponential disposition. J Pharmacokinet Pharmacodyn 28:57–78CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical SciencesState University of New York at BuffaloBuffaloUSA

Personalised recommendations